Baxter International Inc. Stock

Equities

BAX

US0718131099

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:01 2024-06-07 pm EDT 5-day change 1st Jan Change
33.16 USD -0.48% Intraday chart for Baxter International Inc. -2.73% -14.23%
Sales 2024 * 15.11B Sales 2025 * 15.66B Capitalization 16.9B
Net income 2024 * 703M Net income 2025 * 950M EV / Sales 2024 * 1.77 x
Net Debt 2024 * 9.85B Net Debt 2025 * 9.06B EV / Sales 2025 * 1.66 x
P/E ratio 2024 *
18 x
P/E ratio 2025 *
14.8 x
Employees 60,000
Yield 2024 *
3.6%
Yield 2025 *
3.74%
Free-Float 74.27%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Baxter International Inc. Presents at Jefferies 2024 Global Healthcare Conference, Jun-05-2024 09:30 AM
Baxter International Inc. Announces New Data Showing Expanded Hemodialysis, Known as HDX Therapy CI
Citigroup Adjusts Price Target on Baxter International to $38 From $44, Keeps Neutral Rating MT
Transcript : Baxter International Inc. Presents at Bank of America Health Care Conference 2024, May-15-2024 03:00 PM
Baxter International's Clinolipid Injection Approved for Expanded Use in US MT
Baxter International Inc. Secures FDA Approval of Clinolipid (Lipid Injectable Emulsion) Neonatal and Pediatric Indication CI
TD Cowen Downgrades Baxter International to Hold From Buy, Price Target is $40 MT
Declaration of Voting Results by Baxter International Inc CI
Baxter International Keeps Quarterly Cash Dividend at $0.29 a Share, Payable July 1 to Shareholders as of May 31 MT
Baxter International Inc. Declares Quarterly Dividend, Payable on July 1, 2024 CI
UBS Adjusts Price Target on Baxter International to $40 From $42, Maintains Neutral Rating MT
Evercore ISI Adjusts Price Target on Baxter International to $46 From $50 MT
Jefferies Adjusts Price Target on Baxter International to $43 From $45 MT
Stifel Adjusts Baxter International's Price Target to $44 From $50 MT
Baxter International Q1 Adjusted Earnings, Net Sales Gain; Boosts 2024 Adjusted Profit Guidance MT
More news
1 day-0.48%
1 week-2.73%
Current month-2.73%
1 month-7.24%
3 months-24.24%
6 months-8.27%
Current year-14.23%
More quotes
1 week
32.76
Extreme 32.76
34.38
1 month
32.76
Extreme 32.76
36.15
Current year
32.76
Extreme 32.76
44.01
1 year
31.01
Extreme 31.01
50.21
3 years
31.01
Extreme 31.01
89.70
5 years
31.01
Extreme 31.01
95.19
10 years
31.01
Extreme 31.01
95.19
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 15-09-30
Director of Finance/CFO 54 23-10-17
Chief Tech/Sci/R&D Officer - 16-12-31
Members of the board TitleAgeSince
Director/Board Member 73 17-02-05
Director/Board Member 64 22-05-09
Director/Board Member 64 19-02-17
More insiders
Date Price Change Volume
24-06-07 33.16 -0.48% 5,069,494
24-06-06 33.32 +0.39% 4,846,035
24-06-05 33.19 -0.33% 7,123,486
24-06-04 33.3 -2.29% 5,622,182
24-06-03 34.08 -0.03% 4,443,562

Delayed Quote Nyse, June 07, 2024 at 04:00 pm EDT

More quotes
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows: - medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.); - kidney dialysis drugs and equipment (30.1%); - systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.; - other (20.1%). Export accounts for 52.7% of net sales.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
33.16 USD
Average target price
45.44 USD
Spread / Average Target
+37.03%
Consensus